Last updated on September 2018

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).


Brief description of study

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).

Detailed Study Description

This research study is for people with advanced liver cancer who have never received systemic medicine (affecting the entire body) for advanced liver cancer. This is a randomized, open-label Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib can slow the progression of advanced liver cancer and improve quality of life compared to treatment with sorafenib alone.

To find out more about the study, if you are qualified and how to participate, please visit our PHOCUS trial website by clicking here.

 

 

Clinical Study Identifier: TX143550

Contact Investigators or Research Sites near you

Start Over

Research Site

Research Site
Philadelphia, PA USA
5.69miles
  Connect »